Integrated Diagnostics Holdings Signals Strong, Profitable Growth

Integrated Diagnostics Holdings ((GB:IDHC)) has held its Q4 earnings call. Read on for the main highlights of the call.

Integrated Diagnostics Holdings’ latest earnings call struck an upbeat tone, as management showcased strong top-line growth, expanding margins and healthier cash generation. While they acknowledged geopolitical tensions, FX exposure and heavy reliance on Egypt, executives argued that robust operations, disciplined costs and a solid balance sheet leave the group well placed to navigate regional volatility.

Broad-Based Revenue Surge Underpins Growth Story

Group revenue climbed 37% year-on-year in 2025, a pace that stands out in a challenging regional backdrop. Management highlighted that growth was not just price-driven but reflected both higher testing activity and higher-value services gaining traction across IDH’s main markets.

Volumes, Pricing and Patient Mix All Move in Tandem

Test volumes rose 11% year-on-year, while average revenue per test jumped 24%, showing pricing power and richer test mix. Tests per patient reached 4.6, indicating that IDH is deepening engagement and cross-selling more complex diagnostics per visit rather than relying on one-off tests.

Egypt Remains Growth Engine as Network Scales Out

Egypt contributed 84.6% of group revenue and remained the clear profit driver, confirming IDH’s dependence on its home market. The company added 137 branches in 2025 to reach 724 locations, fueling volume growth and enabling a wider mix of tests as it penetrates more neighborhoods nationwide.

Margins Expand Sharply on Operating Leverage

Gross margin widened to 42.7% from 38.1%, while EBITDA margin approached 34%, up from 29.7% a year earlier. Management credited operating leverage from higher throughput and disciplined overheads, suggesting the business model scales profitably as new branches mature.

Cost Base Tightens Despite Growth Investments

COGS-to-revenue improved to 57.3% from 61.9%, with raw materials dropping to 19.3% of revenue from 22.0%. SG&A fell to 15.0% from 16.9%, even as IDH continued targeted investments in expansion, signaling strong cost control and efficiency gains.

Profits Accelerate and Balance Sheet Strengthens

Adjusted net profit surged 79% year-on-year to EGP 1.26 billion, while reported net income reached EGP 1.3 billion, up 29%. Cash reserves increased to EGP 2.1 billion and net cash nearly doubled to EGP 472 million, giving IDH flexibility to fund growth and absorb shocks.

Working Capital Discipline Boosts Cash Conversion

The cash conversion cycle improved to 104 days at end-2025 from 155 days a year earlier, reflecting tighter inventory and receivables management. This improvement is crucial for a rapidly expanding network, freeing up cash to reinvest in branch rollout and technology.

Radiotherapy Deal Deepens Oncology Offering

The acquisition and integration of Cairo Ray for Radiotherapy broadened IDH’s presence in oncology and radiotherapy services. Management framed this as a strategic step into higher-value, more comprehensive diagnostic and treatment pathways that can lift yields and patient stickiness.

Saudi Arabia Expansion Gains Traction but Needs Time

Biolab KSA posted SAR 5 million in 2025 revenue, up 252% year-on-year, and expanded to three branches. The group plans to reach nine branches by end-2026 and targets SAR 18 million revenue, though management cautioned that Saudi EBITDA is unlikely to turn positive before 2028.

Nigeria Turns the Corner on Profitability

Echo-Lab in Nigeria delivered a full year of positive EBITDA in 2025, a milestone after earlier struggles. The turnaround supports IDH’s view that Nigeria remains a promising long-term market once scale and operational discipline are in place.

Dividend Signals Confidence While Preserving Flexibility

The board declared a USD 0.0085 per share dividend for 2025, totaling USD 4.9 million, offering investors a direct cash return. At the same time, management stressed maintaining balance sheet strength for future M&A, branch rollout and a potential buyback when conditions align.

Geopolitics Cast a Shadow Over Regional Outlook

Management flagged that escalating regional tensions, particularly around the U.S./Israel–Iran axis, could weigh on markets like Jordan and Saudi Arabia. Such instability may impact patient volumes or constrain mobility, reinforcing the importance of IDH’s liquidity and diversified footprint.

Sudan Remains a Minimal Contributor Amid Conflict

Operations in Sudan remain severely constrained, with only a single branch partially operating and no meaningful revenue contribution. Management did not signal any near-term recovery, treating Sudan as a modest optionality rather than a pillar of the investment case.

FX and Import Dependence Create Cost Risk

IDH imports almost all its test kits, leaving the business exposed to currency swings and freight costs. Inventory coverage is secured only until August, meaning any further FX pressures or supply chain disruption later in the year could squeeze margins if not offset by pricing or efficiency.

Adjusting for FX Swings Clarifies Earnings Quality

Management noted that 2024 benefited from a significant FX gain, inflating the prior-year comparison. By emphasizing the 79% rise in adjusted net profit versus the 29% reported increase, the company aimed to highlight underlying operational momentum stripped of nonrecurring FX effects.

Concentration on Egypt Remains a Structural Risk

With 84.6% of revenue generated in Egypt, IDH is highly sensitive to that market’s macro and FX conditions. While the Egyptian business is currently powering growth, any sharp downturn or currency shock could disproportionately affect group earnings.

Execution Critical for CapEx and Branch Pipeline

The group’s aggressive plan to open around 200 branches across Egypt, Saudi and Jordan in 2026, coupled with CapEx near 5.9% of sales, demands disciplined execution. Maintaining margin momentum while ramping new sites will be a key test for management in the coming years.

Guidance Points to Solid 2026 Expansion

For 2026, management expects roughly 25% revenue growth, with about 10% from January price increases and 15% from volume gains, while keeping EBITDA margin around 33–34%. CapEx is pegged at about 5.9% of sales, with most spending in Egypt and around 200 new branches planned across Egypt, Saudi and Jordan, underpinned by a net cash position of EGP 472 million.

IDH’s call painted a picture of a diagnostics group in strong operational shape, combining fast growth with rising margins and improving cash generation. Investors must balance that momentum against FX, geopolitical and concentration risks, but management’s guidance and balance sheet suggest the company is entering its next expansion phase from a position of strength.